APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Carcinoma

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroendocrine Carcinoma Market Outlook and Growth Opportunities 2026

Report ID 174016460422 December 2025198 pages

Choose your research edition.

Industry ResearchNeuroendocrine Carcinoma Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Carcinoma Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Carcinoma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Carcinoma Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Carcinoma Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neuroendocrine Carcinoma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroendocrine Carcinoma market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroendocrine Carcinoma market include Teva, Novartis, Pfizer, Abbvie, Valeant, Mateon, Lexicon, Jubilant and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neuroendocrine Carcinoma market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroendocrine Carcinoma and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroendocrine Carcinoma revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neuroendocrine Carcinoma market.

Neuroendocrine Carcinoma Segment by Company

Teva

Novartis

Pfizer

Abbvie

Valeant

Mateon

Lexicon

Jubilant

Ipsen

F.Hoffmann-La Roche

Chiasma

Advanced Accelerator

Neuroendocrine Carcinoma Segment by Type

Somatostatin Analogs

Chemotherapy

Targeted Therapy

Neuroendocrine Carcinoma Segment by Application

Oncology Centres

Clinics

Hospital

Ambulatory Surgery Centres

Neuroendocrine Carcinoma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroendocrine Carcinoma status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neuroendocrine Carcinoma key companies, revenue, market share, and recent developments.

3. To split the Neuroendocrine Carcinoma breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neuroendocrine Carcinoma market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroendocrine Carcinoma significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroendocrine Carcinoma competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroendocrine Carcinoma industry.

Chapter 3: Detailed analysis of Neuroendocrine Carcinoma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neuroendocrine Carcinoma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neuroendocrine Carcinoma in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroendocrine Carcinoma Industry Trends Table 2. Neuroendocrine Carcinoma Industry Drivers Table 3. Neuroendocrine Carcinoma Industry Opportunities and Challenges Table 4. Neuroendocrine Carcinoma Industry Restraints Table 5. Global Neuroendocrine Carcinoma Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroendocrine Carcinoma Revenue Share by Company (2021-2026) Table 7. Global Neuroendocrine Carcinoma Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neuroendocrine Carcinoma Key Company Manufacturing Base & Headquarters Table 9. Global Neuroendocrine Carcinoma Company, Product Type & Application Table 10. Global Neuroendocrine Carcinoma Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neuroendocrine Carcinoma by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Somatostatin Analogs Table 15. Significant Companies of Chemotherapy Table 16. Significant Companies of Targeted Therapy Table 17. Global Neuroendocrine Carcinoma Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Neuroendocrine Carcinoma Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Neuroendocrine Carcinoma Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Neuroendocrine Carcinoma Sales Value Share by Type (2021-2026) Table 21. Global Neuroendocrine Carcinoma Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Oncology Centres Table 23. Significant Companies of Clinics Table 24. Significant Companies of Hospital Table 25. Significant Companies of Ambulatory Surgery Centres Table 26. Global Neuroendocrine Carcinoma Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neuroendocrine Carcinoma Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Neuroendocrine Carcinoma Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Neuroendocrine Carcinoma Sales Value Share by Application (2021-2026) Table 30. Global Neuroendocrine Carcinoma Sales Value Share by Application (2027-2032) Table 31. Global Neuroendocrine Carcinoma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neuroendocrine Carcinoma Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Neuroendocrine Carcinoma Sales Value Share by Region (2021-2026) Table 34. Global Neuroendocrine Carcinoma Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Neuroendocrine Carcinoma Sales Value Share by Region (2027-2032) Table 36. Global Neuroendocrine Carcinoma Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neuroendocrine Carcinoma Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Neuroendocrine Carcinoma Sales Value Market Share by Country (2021-2026) Table 39. Global Neuroendocrine Carcinoma Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Neuroendocrine Carcinoma Sales Value Market Share by Country (2027-2032) Table 41. Teva Company Information Table 42. Teva Business Overview Table 43. Teva Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Teva Neuroendocrine Carcinoma Product Portfolio Table 45. Teva Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Novartis Neuroendocrine Carcinoma Product Portfolio Table 50. Novartis Recent Development Table 51. Pfizer Company Information Table 52. Pfizer Business Overview Table 53. Pfizer Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Pfizer Neuroendocrine Carcinoma Product Portfolio Table 55. Pfizer Recent Development Table 56. Abbvie Company Information Table 57. Abbvie Business Overview Table 58. Abbvie Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Abbvie Neuroendocrine Carcinoma Product Portfolio Table 60. Abbvie Recent Development Table 61. Valeant Company Information Table 62. Valeant Business Overview Table 63. Valeant Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Valeant Neuroendocrine Carcinoma Product Portfolio Table 65. Valeant Recent Development Table 66. Mateon Company Information Table 67. Mateon Business Overview Table 68. Mateon Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Mateon Neuroendocrine Carcinoma Product Portfolio Table 70. Mateon Recent Development Table 71. Lexicon Company Information Table 72. Lexicon Business Overview Table 73. Lexicon Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Lexicon Neuroendocrine Carcinoma Product Portfolio Table 75. Lexicon Recent Development Table 76. Jubilant Company Information Table 77. Jubilant Business Overview Table 78. Jubilant Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Jubilant Neuroendocrine Carcinoma Product Portfolio Table 80. Jubilant Recent Development Table 81. Ipsen Company Information Table 82. Ipsen Business Overview Table 83. Ipsen Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Ipsen Neuroendocrine Carcinoma Product Portfolio Table 85. Ipsen Recent Development Table 86. F.Hoffmann-La Roche Company Information Table 87. F.Hoffmann-La Roche Business Overview Table 88. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio Table 90. F.Hoffmann-La Roche Recent Development Table 91. Chiasma Company Information Table 92. Chiasma Business Overview Table 93. Chiasma Neuroendocrine Carcinoma Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Chiasma Neuroendocrine Carcinoma Product Portfolio Table 95. Chiasma Recent Development Table 96. Advanced Accelerator Company Information Table 97. Advanced Accelerator Business Overview Table 98. Advanced Accelerator Neuroendocrine Carcinoma Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio Table 100. Advanced Accelerator Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Neuroendocrine Carcinoma Product Image Figure 2. Global Neuroendocrine Carcinoma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Carcinoma Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Somatostatin Analogs Image Figure 8. Chemotherapy Image Figure 9. Targeted Therapy Image Figure 10. Global Neuroendocrine Carcinoma Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Neuroendocrine Carcinoma Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Neuroendocrine Carcinoma Sales Value Share by Type (2021-2032) Figure 13. Oncology Centres Image Figure 14. Clinics Image Figure 15. Hospital Image Figure 16. Ambulatory Surgery Centres Image Figure 17. Global Neuroendocrine Carcinoma Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Neuroendocrine Carcinoma Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Neuroendocrine Carcinoma Sales Value Share by Application (2021-2032) Figure 20. Global Neuroendocrine Carcinoma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Neuroendocrine Carcinoma Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Neuroendocrine Carcinoma Sales Value (2021-2032) & (US$ Million) Figure 23. North America Neuroendocrine Carcinoma Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Neuroendocrine Carcinoma Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Neuroendocrine Carcinoma Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Neuroendocrine Carcinoma Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Neuroendocrine Carcinoma Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Neuroendocrine Carcinoma Sales Value (2021-2032) & (US$ Million) Figure 29. South America Neuroendocrine Carcinoma Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Neuroendocrine Carcinoma Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Neuroendocrine Carcinoma Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Somatostatin Analogs
  • Chemotherapy
  • Targeted Therapy
Applications
  • Oncology Centres
  • Clinics
  • Hospital
  • Ambulatory Surgery Centres
Companies covered
  • Teva
  • Novartis
  • Pfizer
  • Abbvie
  • Valeant
  • Mateon
  • Lexicon
  • Jubilant
  • Ipsen
  • F.Hoffmann-La Roche
  • Chiasma
  • Advanced Accelerator

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuroendocrine Carcinoma Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuroendocrine Carcinoma Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neuroendocrine Carcinoma Market Dynamics
  1. 2.1 Neuroendocrine Carcinoma Industry Trends
  2. 2.2 Neuroendocrine Carcinoma Industry Drivers
  3. 2.3 Neuroendocrine Carcinoma Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Carcinoma Industry Restraints
3 Neuroendocrine Carcinoma Market by Company
  1. 3.1 Global Neuroendocrine Carcinoma Company Revenue Ranking in 2025
  2. 3.2 Global Neuroendocrine Carcinoma Revenue by Company (2021-2026)
  3. 3.3 Global Neuroendocrine Carcinoma Company Ranking (2024-2026)
  4. 3.4 Global Neuroendocrine Carcinoma Company Manufacturing Base and Headquarters
  5. 3.5 Global Neuroendocrine Carcinoma Company Product Type and Application
  6. 3.6 Global Neuroendocrine Carcinoma Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neuroendocrine Carcinoma Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neuroendocrine Carcinoma Market by Type
  1. 4.1 Neuroendocrine Carcinoma Type Introduction
  2. 4.1.1 Somatostatin Analogs
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Targeted Therapy
  5. 4.2 Global Neuroendocrine Carcinoma Sales Value by Type
  6. 4.2.1 Global Neuroendocrine Carcinoma Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroendocrine Carcinoma Sales Value by Type (2021-2032)
  8. 4.2.3 Global Neuroendocrine Carcinoma Sales Value Share by Type (2021-2032)
5 Neuroendocrine Carcinoma Market by Application
  1. 5.1 Neuroendocrine Carcinoma Application Introduction
  2. 5.1.1 Oncology Centres
  3. 5.1.2 Clinics
  4. 5.1.3 Hospital
  5. 5.1.4 Ambulatory Surgery Centres
  6. 5.2 Global Neuroendocrine Carcinoma Sales Value by Application
  7. 5.2.1 Global Neuroendocrine Carcinoma Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neuroendocrine Carcinoma Sales Value by Application (2021-2032)
  9. 5.2.3 Global Neuroendocrine Carcinoma Sales Value Share by Application (2021-2032)
6 Neuroendocrine Carcinoma Regional Value Analysis
  1. 6.1 Global Neuroendocrine Carcinoma Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroendocrine Carcinoma Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neuroendocrine Carcinoma Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neuroendocrine Carcinoma Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuroendocrine Carcinoma Sales Value (2021-2032)
  7. 6.3.2 North America Neuroendocrine Carcinoma Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neuroendocrine Carcinoma Sales Value (2021-2032)
  10. 6.4.2 Europe Neuroendocrine Carcinoma Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neuroendocrine Carcinoma Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neuroendocrine Carcinoma Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neuroendocrine Carcinoma Sales Value (2021-2032)
  16. 6.6.2 South America Neuroendocrine Carcinoma Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neuroendocrine Carcinoma Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neuroendocrine Carcinoma Sales Value Share by Country, 2025 VS 2032
7 Neuroendocrine Carcinoma Country-level Value Analysis
  1. 7.1 Global Neuroendocrine Carcinoma Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroendocrine Carcinoma Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neuroendocrine Carcinoma Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neuroendocrine Carcinoma Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neuroendocrine Carcinoma Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neuroendocrine Carcinoma Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neuroendocrine Carcinoma Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Neuroendocrine Carcinoma Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Neuroendocrine Carcinoma Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Neuroendocrine Carcinoma Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Abbvie
  20. 8.4.1 Abbvie Company Information
  21. 8.4.2 Abbvie Business Overview
  22. 8.4.3 Abbvie Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Abbvie Neuroendocrine Carcinoma Product Portfolio
  24. 8.4.5 Abbvie Recent Developments
  25. 8.5 Valeant
  26. 8.5.1 Valeant Company Information
  27. 8.5.2 Valeant Business Overview
  28. 8.5.3 Valeant Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Valeant Neuroendocrine Carcinoma Product Portfolio
  30. 8.5.5 Valeant Recent Developments
  31. 8.6 Mateon
  32. 8.6.1 Mateon Company Information
  33. 8.6.2 Mateon Business Overview
  34. 8.6.3 Mateon Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mateon Neuroendocrine Carcinoma Product Portfolio
  36. 8.6.5 Mateon Recent Developments
  37. 8.7 Lexicon
  38. 8.7.1 Lexicon Company Information
  39. 8.7.2 Lexicon Business Overview
  40. 8.7.3 Lexicon Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lexicon Neuroendocrine Carcinoma Product Portfolio
  42. 8.7.5 Lexicon Recent Developments
  43. 8.8 Jubilant
  44. 8.8.1 Jubilant Company Information
  45. 8.8.2 Jubilant Business Overview
  46. 8.8.3 Jubilant Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jubilant Neuroendocrine Carcinoma Product Portfolio
  48. 8.8.5 Jubilant Recent Developments
  49. 8.9 Ipsen
  50. 8.9.1 Ipsen Company Information
  51. 8.9.2 Ipsen Business Overview
  52. 8.9.3 Ipsen Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ipsen Neuroendocrine Carcinoma Product Portfolio
  54. 8.9.5 Ipsen Recent Developments
  55. 8.10 F.Hoffmann-La Roche
  56. 8.10.1 F.Hoffmann-La Roche Company Information
  57. 8.10.2 F.Hoffmann-La Roche Business Overview
  58. 8.10.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  59. 8.10.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio
  60. 8.10.5 F.Hoffmann-La Roche Recent Developments
  61. 8.11 Chiasma
  62. 8.11.1 Chiasma Company Information
  63. 8.11.2 Chiasma Business Overview
  64. 8.11.3 Chiasma Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Chiasma Neuroendocrine Carcinoma Product Portfolio
  66. 8.11.5 Chiasma Recent Developments
  67. 8.12 Advanced Accelerator
  68. 8.12.1 Advanced Accelerator Company Information
  69. 8.12.2 Advanced Accelerator Business Overview
  70. 8.12.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio
  72. 8.12.5 Advanced Accelerator Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst